Boundless Bio Inc. (BOLD) Price & Analysis

Compare

36 Followers

BOLD Stock Chart & Stats

$1.23

-$0.03(-1.15%)

At close: Jan 08 4:00 PM EST

$1.23

-$0.03(-1.15%)

Day’s Range― - ―

52-Week Range$1.00 - $3.54

Previous CloseN/A

Volume5.57K

Average Volume (3M)160.02K

Market Cap

$26.19M

Enterprise Value-$40.28M

Total Cash (Recent Filing)$117.57M

Total Debt (Recent Filing)$49.76M

Price to Earnings (P/E)―

Beta1.91

Next Earnings

Mar 26, 2026

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding22,385,610

10 Day Avg. Volume222,566

30 Day Avg. Volume160,016

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.33

Price to Sales (P/S)0.00

P/FCF Ratio-0.78

Enterprise Value/Market Cap-1.54

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit64.24

Enterprise Value/Ebitda0.63

Forecast

1Y Price Target

$4.00

Price Target Upside225.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-2.59

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe BBI-355 (CHK1) / BBI-825 (RNR) combo arm in the POTENTIATE trial is open for enrollment, suggesting potential data in 2026.

Efficacy And SafetyCHK1i + RNRi could achieve meaningful efficacy at tolerable exposures, avoiding the tox ceiling that crippled prior CHK1s.

Financial OutlookThe company reported $127mn in cash reiterating runway into 1H28, and expects PoC clinical readouts for both programs within this timeline.

Bears Say

Past Trial LimitationsPrior trials combined a CHK1 inhibitor and subtherapeutic gemcitabine and demonstrated responses in multiple tumor types, but were limited by hematological toxicities.

Price Target ReductionThe company reported a reduction in price target from $5 to $4 per share.

Boundless Bio Inc. News

Boundless Bio reports Q3 EPS (62c), consensus (58c)

We are advancing a pipeline rooted in tumor-enabling ecDNA biology to bring forward innovative therapies for patients with...

26d ago

BOLD

Boundless Bio sees cash runway into 1H28

Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025. Published first on TheFly...

26d ago

BOLD

Boundless Bio Inc. Reports Q3 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q3 earnings. Here is a breakdown of the information...

25d ago

BOLD

Boundless Bio’s Innovative Cancer Study: A Potential Game-Changer?

Boundless Bio Inc. (($BOLD)) announced an update on their ongoing clinical study. Boundless Bio Inc. (BOLD) is conducting...

1M ago

BOLD

Innovative Cancer Treatment Approach and Promising Outlook Drive Buy Rating for Boundless Bio Inc.

Boundless Bio Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor...

1M ago

BOLD

Hold Rating on Boundless Bio Inc.: Awaiting Clinical Validation of Innovative Therapies

In a report released yesterday, Andrew Berens from Leerink Partners maintained a Hold rating on Boundless Bio Inc.,...

4M ago

BOLD

Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Boundless Bio (BOLD) to $4 from $5 and keeps a...

4M ago

BOLD

Boundless Bio Reports Q2 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

BOLD

Boundless Bio reports Q2 EPS (70c), consensus (65c)

“We are executing with sharpened focus on programs that we believe have the strongest scientific rationale and greatest...

4M ago

BOLD

Boundless Bio initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio (BOLD) with an Early-Stage Biotech rating, saying the...

4M ago

BOLD

Boundless Bio Elects Directors and Ratifies Auditor

Boundless Bio Inc. ( ($BOLD) ) just unveiled an update. At the annual meeting of stockholders held on...

5M ago

BOLD

Boundless Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Boundless Bio (BOLD) with a Buy rating and $5 price target Boundless is...

6M ago

BOLD

Boundless Bio Inc. Reports Q1 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q1 earnings. Here is a breakdown of the information...

6M ago

BOLD

Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations

In a report released today, Andrew Berens from Leerink Partners downgraded Boundless Bio Inc. (BOLD – Research Report)...

6M ago

BOLD

BOLD FAQ

What was Boundless Bio Inc.’s price range in the past 12 months?

Boundless Bio Inc. lowest stock price was $1.00 and its highest was $3.54 in the past 12 months.

What is Boundless Bio Inc.’s market cap?

Boundless Bio Inc.’s market cap is $26.19M.

When is Boundless Bio Inc.’s upcoming earnings report date?

Boundless Bio Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 115 days.

How were Boundless Bio Inc.’s earnings last quarter?

Boundless Bio Inc. released its earnings results on Nov 05, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.582 by -$0.038.

Is Boundless Bio Inc. overvalued?

According to Wall Street analysts Boundless Bio Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Boundless Bio Inc. pay dividends?

Boundless Bio Inc. does not currently pay dividends.

What is Boundless Bio Inc.’s EPS estimate?

Boundless Bio Inc.’s EPS estimate is -0.52.

How many shares outstanding does Boundless Bio Inc. have?

Boundless Bio Inc. has 22,385,610 shares outstanding.

What happened to Boundless Bio Inc.’s price movement after its last earnings report?

Boundless Bio Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.582. Following the earnings report the stock price went down -3.077%.

Which hedge fund is a major shareholder of Boundless Bio Inc.?

Currently, no hedge funds are holding shares in BOLD

Company Description

Boundless Bio Inc.

Boundless Bio Inc. (BOLD) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in targeting extrachromosomal DNA (ecDNA) in cancer cells, aiming to address genomic amplification and improve treatment outcomes. Boundless Bio operates within the biopharmaceutical sector, leveraging cutting-edge research to create products that can potentially transform cancer care.

Boundless Bio Inc. (BOLD) Earnings & Revenues

Historic Earnings Reports

BOLD Stock 12 Month Forecast

Average Price Target

$4.00

▲(225.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.23,1.4430769230769231,1.656153846153846,1.8692307692307693,2.082307692307692,2.2953846153846156,2.5084615384615385,2.7215384615384615,2.934615384615385,3.147692307692308,3.3607692307692307,3.5738461538461537,3.786923076923077,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.23,1.4430769230769231,1.656153846153846,1.8692307692307693,2.082307692307692,2.2953846153846156,2.5084615384615385,2.7215384615384615,2.934615384615385,3.147692307692308,3.3607692307692307,3.5738461538461537,3.786923076923077,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.23,1.4430769230769231,1.656153846153846,1.8692307692307693,2.082307692307692,2.2953846153846156,2.5084615384615385,2.7215384615384615,2.934615384615385,3.147692307692308,3.3607692307692307,3.5738461538461537,3.786923076923077,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >